Table 1.
Recent studies on renal denervation in hypertension and BP-lowering effects
| Title | Number | Year | Condition | Comparator | Systolic blood pressure reduction |
|---|---|---|---|---|---|
| Spryal-HTN-Off-MED [24] | 80 | 2017 | Off-med cohort | RDN vs. Sham (1:1) | 5.5 mmHg (ABPM) 10.0 mmHg (OBP) |
| SPYRAL-HTN-ON-MED [23] | 80 | 2018 | 50% resistant hypertension | RDN vs. Sham (1:1) | 9.0 mmHg (ABPM) 9.4 mmHg (OBP) |
| RADIANCE-SOLO [21] | 146 | 2018 | Off-med cohort | RDN vs. Sham (1:1) | 7.0 mmHg (ABPM) 10.8 mmHg (OBP) |
| 3-year follow-up from the Global SYMPLICITY Registry [25] | 1742 | 2019 | Hypertension with 4.5 drug classes on average | None (single-arm) | 8.0 mmHg (ABPM) 16.5 mmHg (OBP) |
| Alcohol-mediated renal denervation using the Peregrine System [26] | 45 | 2020 | Resistant hypertension | None (single-arm) | 11.0 mmHg (ABPM) 18.0 mmHg (OBP) |
| SPRYAL-Off-MED-PIVOTAL [22] | 331 | 2020 | Off-med cohort | RDN vs. Sham (1:1) | 4.7 mmHg (ABPM) 9.2 mmHg (OBP) |
| RADIANCE-TRIO [20] | 136 | 2021 | Resistant hypertension | RDN vs. Sham (1:1) | 8.5 mmHg (ABPM) 9.0 mmHg (OBP) |
ABPM ambulatory blood pressure measurement, OBP office blood pressure